Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston, MA 02210
Phone: (617) 341-6100Website: https://www.vrtx.com/Careers: vrtx.wd5.myworkdayjobs.com/vertex_careersPatient Assistance Program: www.vrtx.com/medicines/patient-support
Latest news
- Vertex Announces Positive Results From the VX-548 Phase 3 Program for the Treatment of Moderate-to-Severe Acute Pain
30 January 2024 - Vertex Announces Publication of VX-548 Positive Phase 2, Proof-of-Concept Results in New England Journal of Medicine
3 August 2023 - Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 2 Through 5 With Certain Mutations
26 April 2023 - Vertex Announces U.S. FDA Approval for Orkambi (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to <24 months
2 September 2022 - Vertex Advances VX-548 in Acute and Neuropathic Pain
22 July 2022 - Vertex Announces Statistically Significant and Clinically Meaningful Results From Two Phase 2 Proof-of-Concept Studies of VX-548 for the Treatment of Acute Pain
31 March 2022 - Vertex Initiates Phase 2 Clinical Trial Program for VX-548 for the Treatment of Acute Pain
19 July 2021 - Vertex Announces U.S. FDA Approval for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) in Children With Cystic Fibrosis Ages 6 through 11 With Certain Mutations
9 June 2021 - Vertex Announces FDA Approvals of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko (tezacaftor/ivacaftor and ivacaftor) and Kalydeco (ivacaftor) for Use in People With CF With Certain Rare Mutations
21 December 2020 - FDA Approves Kalydeco (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With CF as Early as Four Months of Age
25 September 2020
Drugs Associated with Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated manufactures, markets and/or distributes more than 5 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Brand/Generic Name | Reviews | Rating |
---|---|---|
Casgevy
Generic name: exagamglogene autotemcel Drug class: miscellaneous uncategorized agents |
||
Kalydeco
Generic name: ivacaftor Drug class: CFTR potentiators |
1 review | 10 / 10 |
Orkambi
Generic name: ivacaftor/lumacaftor Drug class: CFTR combinations |
||
Symdeko
Generic name: ivacaftor/tezacaftor Drug class: CFTR combinations |
||
Trikafta
Generic name: elexacaftor/ivacaftor/tezacaftor Drug class: CFTR combinations |
1 review | 9.0 / 10 |
For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective). |